A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Mine Harada, Tsunefumi Shibuya, Takanori Teshima, Masahiro Murakawa, Takashi Okamura, Yoshiyuki Niho, Hisashi Gondo, Shin Hayashi, Koichi Akashi, Kazuo Tamura, Shigeyoshi Makino, Hideyo Natori, Koichiro Egami, Shusuke Hisano, Eiji Morioka, Shuichi Taniguchi, Kazuo Yamazaki, Yujiro Yamano, Fusayuki Omori

研究成果: ジャーナルへの寄稿学術誌査読

6 被引用数 (Scopus)

抄録

We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.

本文言語英語
ページ(範囲)629-632
ページ数4
ジャーナルLeukemia Research
17
8
DOI
出版ステータス出版済み - 8月 1993
外部発表はい

!!!All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学
  • 癌研究

フィンガープリント

「A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル